摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)-2-methylpropan-2-ol | 862844-47-1

中文名称
——
中文别名
——
英文名称
1-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)-2-methylpropan-2-ol
英文别名
1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]-2-methylpropan-2-ol;1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c][1,5]naphthyridin-1-yl]-2-methylpropan-2-ol
1-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)-2-methylpropan-2-ol化学式
CAS
862844-47-1
化学式
C16H21N5O2
mdl
——
分子量
315.375
InChiKey
FVHQMODUIGOFJT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    99.1
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • Method of Preferentially Inducing the Biosynthesis of Interferon
    申请人:Kshirsagar Tushar A.
    公开号:US20090030031A1
    公开(公告)日:2009-01-29
    A method of preferentially inducing IFN-α biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-α biosynthesis in an animal are disclosed.
    本发明涉及一种优先诱导动物中IFN-α生物合成的方法,包括给予在2-位具有羟甲基或羟乙基取代基的某些咪唑[4,5-c]环化合物或含有这些化合物的药物组成物,中间体,制备方法和使用这些化合物的方法作为免疫调节剂,用于治疗包括病毒和肿瘤疾病在内的疾病,其中包括优先诱导动物中IFN-α生物合成。
  • Hydroxyalkyl Substituted Imidazonaphthyridines
    申请人:Kshirsagar Tushar A.
    公开号:US20090253695A1
    公开(公告)日:2009-10-08
    Certain imidazonaphthyridines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
    本发明揭示了在2位具有羟甲基或羟乙基取代基的咪唑萘啶类化合物、含有这些化合物的制药组合物、中间体、制备方法以及将这些化合物作为免疫调节剂的使用方法,用于在动物体内优先诱导IFN-α合成,并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
  • Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
    申请人:3M Innovative Properties Company
    公开号:US08178539B2
    公开(公告)日:2012-05-15
    Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalene-9-amines, pharmaceutical compositions containing the compounds or salts thereof, intermediates, methods of making the compounds or salts thereof, and methods of use of these compounds or salts thereof or pharmaceutical compositions as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    本文介绍了3,4,6,7-四氢-5H-1,2a,4a,8-四氮杂环戊-[cd]吩啶-9-胺及其盐的替代物、含有该化合物或其盐的制药组合物、中间体、制备该化合物或其盐的方法,以及将这些化合物或其盐或制药组合物用作免疫调节剂的方法,用于诱导动物细胞因子生物合成和治疗包括病毒和肿瘤疾病在内的疾病。
  • Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods
    申请人:Griesgraber George W.
    公开号:US20100173906A1
    公开(公告)日:2010-07-08
    Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalene-9-amines, pharmaceutical compositions containing the compounds or salts thereof, intermediates, methods of making the compounds or salts thereof, and methods of use of these compounds or salts thereof or pharmaceutical compositions as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
    本发明涉及3,4,6,7-四氢-5H-1,2a,4a,8-四氮杂环戊[cd]菲啰啉-9-胺及其盐的替代物,含有该化合物或其盐的制药组合物,中间体,制备该化合物或其盐的方法,以及将这些化合物或其盐或制药组合物用作免疫调节剂的方法,用于诱导动物细胞因子生物合成和治疗包括病毒性和肿瘤性疾病在内的疾病。
  • SULFONE SUBSTITUTED IMIDAZO RING ETHERS
    申请人:3M Innovative Properties Company
    公开号:EP1694674A2
    公开(公告)日:2006-08-30
查看更多